Hamlin P, Farber C, Fenske T, et al. The dual SYK/JAK inhibitor cerdulatinib demonstrates complete inhibition of SYK and JAK and rapid tumor responses in a phase 2 study in patients with relapsed/refractory B cell malignancies. EHA 2017, abstract S773.
Versnelde FDA-goedkeuring loncastuximab tesirine bij grootcellig B-cellymfoom
mei 2021 | Lymfoom